Evidence map›Paper›PMID 40523759›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025

EZH2 promotes malignant biological behavior in esophageal squamous cell carcinoma via EMT.

Yuying Jing, Kaige Yang, Yiting Cheng, Tianping Huang, Sufang Chen, Kai Chen, Jianming Hu

Abstract read
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuying JingDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002. 623199820@qq.com.
Kaige YangDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002.
Yiting ChengDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002.
Tianping HuangDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002.
Sufang ChenDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002.
Kai ChenDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002.
Jianming HuDepartment of Pathology, School of Medicine, Shihezi University, Shihezi 832002. jianming.120@163.com.

Funding

the Basic Research Project of Shihezi University MSPY202407the Gastrointestinal Early Cancer Physician Common Growth Plan Research Project GTCZ-2023-XJ-02the Guiding Scientific and Technological Research Project in the Xinjiang Production and Construction Corps 2022ZD003 and 2023AB058the Shihezi University Independently Funded Research and Innovation Project ZZZC2023029the Shihezi University Undergraduate Research Training Program SRP2024459
6 · The paper itself

Abstract

objectivesEsophageal squamous cell carcinoma (ESCC) is characterized by complex pathogenesis and poor prognosis. In recent years, epithelial-mesenchymal transition (EMT) in tumor initiation and progression has attracted increasing attention. Enhancer of zeste homolog 2 (EZH2), which is aberrantly expressed in various tumors, may be closely related to the EMT process. This study aims to examine the expression and correlation of EZH2 and EMT markers in ESCC cells and tissues, evaluate the effects of

methodsBioinformatics analyses were used to assess EZH2 expression levels in ESCC. Small interfering RNA was used to knock down

resultsBioinformatics analysis showed that

conclusionsEZH2 promotes malignant biological behavior in ESCC by mediating EMT. Elevated EZH2 expression is associated with poor prognosis in ESCC patients.

Indexed as

Enhancer of Zeste Homolog 2 ProteinEpithelial-Mesenchymal TransitionEsophageal NeoplasmsCadherinsCell Line, TumorCell MovementCell ProliferationEsophageal Squamous Cell CarcinomaFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm InvasivenessPrognosisRNA, Small InterferingCadherinsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanRNA, Small InterferingVimentinVIM protein, humanenhancer of zeste homolog 2epithelial-mesenchymal transitionesophageal squamous cell carcinomamalignant biological behaviorprognosis

Identifiers

PMID40523759
PMCPMC13346017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.